Multiple clinical trials evaluating CDK4/6 inhibitors in patients with HR+/HER2- high-risk breast cancer have reported positive results, but many oncologists are reluctant to use these agents as ...
or on the link below. Despite positive results from randomized clinical trials (RCTs) evaluating CDK4/6 inhibitors in patients with hormone receptor–positive, human epidermal growth factor receptor ...
This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting I. This abstract does not include a full text component.
Signatera™ will be used to identify patients who may be able to delay or defer adjuvant CDK4/6 inhibitor therapy in intermediate-risk HR+/HER2- breast cancer SIGNAL is a new group of Natera-sponsored ...
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts. In fact, results from the failed ...
In addition, CDK4/6 inhibitors appear to confer a comparable relative benefit in both premenopausal and postmenopausal patients. 7,8 There are no tumor biomarkers that predict benefit of CDK4/6 ...
Estimated time to complete this activity: 1 hour. This activity has been approved for a maximum of 1.0 AMA PRA Category 1 Credits™. Fees and Prerequisites: There are no fees or prerequisites.
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Women with advanced breast cancer had similar overall ...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Dr ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results